Year None20232022202120202019 Jun 06, 2023 Arcutis to Present at Upcoming Investor Conference Jun 05, 2023 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 24, 2023 Arcutis Announces Leadership Transition May 09, 2023 Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update May 05, 2023 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2023 Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for Apr 28, 2023 Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psor Apr 25, 2023 Arcutis to Report First Quarter Financial Results Apr 18, 2023 Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 9 of 21
